90Y-Epratuzumab Study Shows Improvement of Therapy Results Following R-CHOP
June 10, 2013 at 16:35 PM EDT
Immunomedics (Nasdaq: IMMU ), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today reported that adding two doses of epratuzumab labeled with the radioisotope, yttrium-90 (90Y), to a combination of rituximab and CHOP chemotherapy
